"Iyeza elimangalisayo lokunciphisa umzimba" liza kungena eTshayina!I-Novo Nordisk yaseChina iqinisekisa inguqu yokulahlekelwa kwesisindo se-Semaglutide iya kuvunywa kulo nyaka

"Iyeza elimangalisayo lokunciphisa umzimba" liza kungena eTshayina!I-Novo Nordisk yaseChina iqinisekisa inguqu yokulahlekelwa kwesisindo se-Semaglutide iya kuvunywa kulo nyaka
Ngomhla we-8 ka-Matshi, iindaba ezithi uNovo Nordisk kulindeleke ukuba inguqu yokulahlekelwa kwesisindo se-Semaglutide Wegovy iya kuvunywa e-China kulo nyaka, imveliso iya kuba yisiqalo sezigulane ezizixhasa ngemali, kwaye kukho umda kwinani lezigulane.Ngokubhekiselele koku, uNovo Nordisk China uqinisekisile ezi ndaba zingasentla kwintatheli yeendaba, "ejonge ukuvunywa kulo nyaka, ngokukhawuleza ukuba kuxhamle izigulana ezityebileyo zaseTshayina."

I-Wegovy ligama lesiNgesi lokurhweba kwi-GLP-1 yeziyobisi i-Semaglutide ephuhliswe nguNovo Nordisk yezibonakaliso zokulahlekelwa kwesisindo, eyavunywa njengeyeza lokunciphisa umzimba ngoJuni 2021 e-United States.I-CEO ye-Tesla u-Musk wakha wakhankanya kumajelo asekuhlaleni ukuba wasebenzisa iyeza lokunciphisa umzimba, kwaye wayekhe wafunwa njenge "chiza elimangalisayo lokunciphisa umzimba".

E-China, i-Semaglutide injection kunye neziyobisi zomlomo zivunyiwe kuphela izibonakaliso zesifo sikashukela, apho i-simethicone injection iya kuvunyelwa ukuthengisa e-China ngo-Ephreli 2021, kwaye emva koko ifake ikhathalogu ye-inshurensi yezempilo kwi-2022;I-oral Semaglutide yavunywa ngoJanuwari kulo nyaka, kwaye yaba yinto yokuqala yomlomo ye-GLP-1 ichiza elivunyiweyo lokuthengisa eChina.

Njengommeli weziyobisi ze-GLP-1, i-Semaglutide iphumelele ngokurhweba.Ingxelo yezemali ye-Novo Nordisk ka-2023 ibonise ukuba intengiso ye-Wegovy inyuke nge-406% ukuya kwi-4.6 yeebhiliyoni zeedola, ikhokelela kwi-GLP-1 track yehlabathi.Kwakhona ngenxa yoko, ezininzi iinkampani zamachiza zasekhaya zibeka i-Semaglutide biosimilar uphuhliso lweziyobisi, kodwa uninzi lukwinqanaba lokuqala leklinikhi, njengeLiju Group (000513), i-Han Yu Pharmaceutical (300199) kunye nezinye iinkampani zamachiza ngaphambili zibhengeze ukuba iSemaglutide yenkampani. inaliti yamkelwa ukuba iqhube ulingo lwezonyango lwezalathisi ezinxulumene nolawulo lobunzima.

Kuyafaneleka ukukhankanya ukuba, kunye noNovo Nordisk yaziwa ngokuba yi "GLP-1 duo" LLY iphinda ikhuthaze uluhlu lweGLP-1 yeyeza lokunciphisa umzimba iTirzepatide eChina, ekulindeleke ukuba ivunywe ekhaya.2023 Agasti, LLY I-China ibhengeze ukuba, ngokutsho kwewebhusayithi esemthethweni yeZiko loVavanyo lweZiyobisi loLawulo lweZiyobisi likaRhulumente.Isicelo sokubhaliswa kwe-injection ye-Tirzepatide yokuphucula ulawulo lwexesha elide kwizigulane ezityebileyo kunye nokukhuluphala kwabantu abadala okanye ubuncinane obunye ubunzima obunxulumene ne-comorbidity kwisiseko sokutya okuphantsi kweekhalori kunye nokunyuka kokuzivocavoca kuye kwamkelwa ngokusemthethweni.

Isalathiso sesifo seswekile seTirzepatide samkelwa e-US ngoMeyi ka-2022, kwaye ichiza lanikela ngeedola ezingama-483 ezigidi kwingeniso kuLilly ngo-2022. iinyanga ezimbini ngaphantsi kwe 176 yezigidi zeerandi kwingeniso.

NgeNovo Nordisk kunye neLLY GLP-1 iziyobisi ekulindeleke ukuba zivunywe ngezalathiso zokuncipha kobunzima eTshayina, ukhuphiswano phakathi kweNovo Nordisk kunye neLLY kwingoma ye-GLP-1 inokuqala kungekudala eTshayina.